Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 23/2/2018
SIETES contiene 92199 citas

 
 
 1 a 20 de 45 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Thiele EA, French ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K, on behalf of the GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018:24 de enero. [Ref.ID 102450]
2.
Whitlock J. Cannabis-derived drug granted priority review. San Diego Business Journal 2018:2 de enero. [Ref.ID 102441]
3. Cita con resumen
Nugent SM, Morasco BJ, O'Neil ME, Freeman M, Low A, Kondo K, Elven C, Zakher B, Motu'apuaka M, Paynter R, Kansagara D. The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann Intern Med 2017;167:319-31. [Ref.ID 102022]
4.Tiene citas relacionadas Cita con resumen
Devinsky O, Cross JH, Wright S. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;377:699-700. [Ref.ID 102019]
5.Tiene citas relacionadas Cita con resumen
Tang R, Fang F. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;377:699. [Ref.ID 102018]
6. Cita con resumen
Russo EB. Cannabidiol claims and misconceptions. Trends Pharmacol Sci 2017;38:198-201. [Ref.ID 101988]
7.Tiene citas relacionadas Cita con resumen
Berkovic SF. Cannabinoids for epilepsy — Real data, at last. N Engl J Med 2017;376:2075-6. [Ref.ID 101596]
8.Tiene citas relacionadas Cita con resumen
Devinsky O, Cross JH, Laux L, Marsh E, Nabbout R, Scheffer IE, Thiele EA, Wright S, for the Cannabidiol in Dravet Syndrome Study Group. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;376:2011-20. [Ref.ID 101595]
9. Cita con resumen
Anónimo. Brazil issues first license for sale of cannabis-based drug. DIA Daily 2017:1. [Ref.ID 101349]
11. Cita con resumen
Anónimo. Cannabis and cannabinoids. Med Lett Drugs Ther 2016;58:97-8. [Ref.ID 100510]
12. Cita con resumen
Rubin R. Senators urge expedited evaluation of medical use of cannabidiol. JAMA 2016;316:13 de julio. [Ref.ID 100491]
14. Cita con resumen
McCall C. Momentum grows for medical use of cannabis. Lancet 2015;386:1615-6. [Ref.ID 99633]
15. Cita con resumen
Friedman D, Devinsky O. Cannabinoids in the treatment of epilepsy. N Engl J Med 2015;373:1048-58. [Ref.ID 99459]
16. Cita con resumen
Anónimo. Study: marijuana extract “showing great promise” as epilepsy treatment. DIA Daily 2015:14 de abril. [Ref.ID 98944]
17. Cita con resumen
Monte AA, Zane RD, Heard KJ. The implications of marijuana legalization in Colorado. JAMA 2015;313:241-2. [Ref.ID 98737]
18. Cita con resumen
Anónimo. delta-9-tétrahydrocannabinol + cannabidiol (Sativex). Prescrire 2014;34:246-50. [Ref.ID 97431]
19. Cita con resumen
Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee R, Mechoulam R, Martínez-Orgado J. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?. Br J Clin Pharmacol 2013;75:323-33. [Ref.ID 94852]
20.Enlace a cita original
Stanley CP, Hind WH, O'Sullivan SE. Is te cardiovascular system a therapeutic target for cannabidiol?. Br J Clin Pharmacol 2013;75:313-22. [Ref.ID 94851]
Seleccionar todas
 
 1 a 20 de 45 siguiente >>